Multiple Myeloma · line 3 · Elranatamab BCMA × CD3 bispecific monotherapy — SC weekly then q2-weekly (MagnetisMM-3)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 3 |
|---|---|
| Track | aggressive |
| Linked regimen | REGIMEN-ELRANATAMAB-MONO-MM |
| ID | IND-MM-RR-3L-ELRANATAMAB |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-29 | pending_clinical_signoff |
| Diseases | DIS-MM |
| Sources | SRC-ESMO-MM-2023 SRC-NCCN-MM-2025 |
Notes
STUB — requires two clinical co-lead signoffs before publication (CHARTER §6.1). Pivotal trial source MagnetisMM-3 (Lesokhin 2023 Nat Med) NOT YET in KB; commit body flags this gap. NCCN-MM-2025 + ESMO-MM-2023 satisfy Q4 ≥2-source axis pending MagnetisMM-3 ingestion.
Used By
No reverse references found in the YAML corpus.